Form 4: Spruce Biosciences Director's Stock Option Repricing

Spruce Biosciences director Percival Barretto-Ko's stock options were repriced to $104.13 per share following a reverse stock split and a company-wide option repricing.

Summary

• Percival Barretto-Ko, a Director at Spruce Biosciences, Inc. (SPRB), reported changes in beneficial ownership of derivative securities.
• The company effected a 1-for-75 reverse stock split on August 4, 2025, which automatically combined 75 shares of common stock into one and adjusted stock options and their exercise prices accordingly.
• On December 11, 2025, a one-time stock option repricing occurred for options with exercise prices of $106.09 per share or greater, held by employees and directors in continuous service.
• The exercise price for eligible options was reduced to $104.13 per share, based on the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date.
• A retention period of one year applies, requiring payment of the original exercise price if options are exercised before its end (unless certain circumstances shorten the period).
• Percival Barretto-Ko's 800 stock options, originally with an exercise price of $169.50, were repriced to $104.13 per share.
• These options vest in equal monthly installments over a three-year period, fully vesting on May 25, 2026, subject to continuous service, and vest in full upon a Change in Control.

Sentiment

Score: 3

Explanation: The reverse stock split and option repricing, while intended to re-incentivize, generally reflect a significant prior decline in stock value and potential underlying challenges, leading to a negative sentiment. The repricing itself is a positive for option holders but stems from a negative event.

Positives

• The option repricing reduces the exercise price for eligible options, potentially increasing their in-the-money value for option holders and re-incentivizing management and directors.
• Aligning option exercise prices with the current market value can improve the effectiveness of equity incentives for retaining and motivating key personnel.

Negatives

• The 1-for-75 reverse stock split, effective August 4, 2025, often indicates a significant decline in the company's share price and can be perceived negatively by the market, potentially signaling underlying financial challenges.
• The need for a stock option repricing from an original exercise price of $169.50 to $104.13 per share suggests a substantial prior decline in the company's stock price, rendering previous options significantly out-of-the-money.
• The one-year retention period for repriced options means immediate exercise at the new lower price is not fully available without penalty, which could delay the realization of benefits for option holders.

Risks

• The reverse stock split could indicate ongoing challenges with the company's stock performance or financial health, potentially impacting investor confidence.
• The necessity of an option repricing suggests that previous equity incentives were ineffective due to significant stock price depreciation, which may reflect broader operational or market risks.
• Future stock price performance could negate the benefits of the repricing if the stock continues to decline, potentially leading to further disincentivization.

Future Outlook

The filing primarily reports past transactions and changes to existing options. It does not provide explicit forward-looking statements or guidance on company performance, but the repricing aims to re-incentivize management and directors for future performance.

Industry Context

Reverse stock splits are often undertaken by biotechnology companies with low stock prices to meet exchange listing requirements or to make the stock more attractive to institutional investors. Option repricings are typically implemented when a company's stock price has significantly declined, rendering existing options out-of-the-money and ineffective as incentives. This suggests Spruce Biosciences may have experienced significant stock price depreciation, a common challenge in the volatile biotech sector, particularly for companies in clinical development stages.

Comparison to Industry Standards

• Reverse stock splits, especially with a high ratio like 1-for-75, are common for biotech companies experiencing significant stock price declines, often to maintain Nasdaq listing standards or improve stock liquidity. For instance, companies like Aeterna Zentaris Inc. (AEZS) or Sorrento Therapeutics (SRNE) have executed similar splits under challenging market conditions.
• Option repricings are a frequent practice in the biotech sector, particularly for small-cap companies with high stock volatility. This strategy is used to re-align executive and director incentives after substantial stock price drops, similar to actions taken by companies such as Zymeworks Inc. (ZYME) to ensure continued motivation.
• The substantial 1-for-75 reverse split ratio indicates a more aggressive measure compared to typical 1-for-5 or 1-for-10 splits seen in more stable industries, highlighting the extent of the prior share value decline.

Corporate Governance

Stakeholder Impact

• Shareholders: The reverse stock split reduces the number of outstanding shares, potentially increasing the per-share price but not the overall market capitalization. The underlying reason for these actions (poor stock performance) is generally negative for existing shareholders.
• Employees/Directors (Option Holders): The repricing makes their out-of-the-money options more valuable, re-incentivizing them and potentially improving retention.

Next Steps

• The repriced stock options will continue to vest monthly until May 25, 2026, subject to the reporting person's continuous service.
• The one-year retention period for repriced options will need to be observed before option holders can exercise at the new lower price without penalty.

Key Dates

Recommendation

The company has undertaken a significant 1-for-75 reverse stock split and a broad stock option repricing. While the repricing aims to re-incentivize management and directors by lowering option exercise prices, these actions typically follow a substantial decline in the company's stock value, indicating underlying operational or market challenges. The reverse split, while potentially helping with listing requirements, does not fundamentally change the company's valuation. Investors should hold to observe if these measures lead to improved operational performance and stock price stability, as the immediate implications are mixed, stemming from past negative performance.

Keywords

Spruce Biosciences, SPRB, Form 4, Stock Option Repricing, Reverse Stock Split, Insider Transaction, Director Compensation, Equity Incentive Plan, Corporate Governance